Clearbridge Health (SGX:1H3) entered into a binding term sheet with Chen Yan and Lim Chee Yong for the acquisition of Elpis Biopharmaceuticals, according to a Monday filing with the Singapore Exchange.
The total consideration payable is $330 million which will be fully satisfied by the issuance and allotment of new shares in the capital of the company.
The proposed acquisition will be completed within four weeks from the satisfaction of certain conditions.
The target company is engaged in the business of medical research and cell therapies for the treatment of solid tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。